Table 3.
Adult infliximab PopPK studies used for allometric scaling
| Study | N | Age, years | Weight, kg | CL, mL/h | Q, mL/h | V1, L | V2, L |
|---|---|---|---|---|---|---|---|
| Inflammatory bowel disease | |||||||
| Fasanmade et al.51 | 580 | 37.5 ± 11.9 | 71.1 ± 18.3 | 15.27 | 6.09 | 3.58 | 1.29 |
| Fasanmade et al.52 | 482 | 41.2 ± 13.9 | 78.8 ± 18.4 | 16.96 | 297.5 | 3.29 | 4.13 |
| Ternant et al.53 | 33 | 33 [19–53] | 67 [44–110] | 12 | 5.4 | 2.9 | 1.9 |
| Dotan et al.54 | 54 | 35.6 [20–70] | NA | 15.8 | 5.08 | 2.37 | 1.37 |
| Aubourg et al.55 | 133 | NA | 60 [41–120] | 14 | 83 | 2.6 | 4.5 |
| Buurman et al.56 | 42 | 44 [19–80] | 75 [51–145] | 8.29 | 2.58 | 4.94 | 3.13 |
| Brandse et al.39 | 332 | 38.6 ± 13.9 | 72.3 ± 16.3 | 14.96 | 2.9 | 4.72 | 2.4 |
| Rheumatoid arthritis | |||||||
| Ternant et al.57 | 84 | 58 [27–84] | 65 | 19 | 180 | 2.3 | 3.6 |
Data presented as mean or median and [range], (interquartile range), or ± SD.
CL, clearance; NA, not applicable; PopPK, population pharmacokinetic; Q, intercompartmental clearance. V1, volume in the central compartment; V2, volume in the peripheral compartment.